MYRIAD GENETICS, INC. (MYGN) Gross Margin
- Gross margin · 12 months: Value 68.83%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 68.83% | Gross profit / revenue. Period ending 2026-06-30. $555.20M ÷ $806.60M × 100 ≈ 68.83% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 555.20M USD | Gross Profit |
| Revenue | 806.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 251.40M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $555.20M | $806.60M | $251.40M | 68.83% |
| 2026-03-31 | $580.00M | $829.00M | $249.00M | 69.96% |
| 2025-12-31 | $576.60M | $824.50M | $247.90M | 69.93% |
| 2025-09-30 | $580.70M | $825.30M | $244.60M | 70.36% |
| 2025-06-30 | $586.60M | $832.90M | $246.30M | 70.43% |
| 2025-03-31 | $582.00M | $831.30M | $249.30M | 70.01% |
| 2024-12-31 | $585.40M | $837.60M | $252.20M | 69.89% |
| 2024-09-30 | (m) | $823.60M | (m) | (m) |
| 2024-06-30 | (m) | $802.20M | (m) | (m) |
| 2024-03-31 | (m) | $774.20M | (m) | (m) |
| 2023-12-31 | (m) | $753.20M | (m) | (m) |
| 2023-09-30 | (m) | $734.40M | (m) | (m) |
| 2023-06-30 | (m) | $698.90M | (m) | (m) |
| 2023-03-31 | (m) | $694.70M | (m) | (m) |
| 2022-12-31 | (m) | $678.40M | (m) | (m) |
| 2022-09-30 | (m) | $661.40M | (m) | (m) |
| 2022-06-30 | (m) | $672.30M | (m) | (m) |
| 2022-03-31 | (m) | $682.40M | (m) | (m) |
| 2021-12-31 | (m) | $690.60M | (m) | (m) |
| 2021-09-30 | (m) | $684.40M | (m) | (m) |
| 2021-06-30 | (m) | $662.30M | (m) | (m) |
| 2021-03-31 | (m) | $566.10M | (m) | (m) |
| 2020-12-31 | (m) | $557.00M | (m) | (m) |
| 2020-09-30 | (m) | $597.50M | (m) | (m) |
| 2020-06-30 | (m) | $638.60M | (m) | (m) |
| 2020-03-31 | (m) | $760.80M | (m) | (m) |
| 2019-12-31 | (m) | $813.40M | (m) | (m) |
| 2019-09-30 | (m) | $835.10M | (m) | (m) |
| 2019-06-30 | (m) | $851.10M | (m) | (m) |
| 2019-03-31 | (m) | $858.50M | (m) | (m) |
| 2018-12-31 | (m) | $825.00M | (m) | (m) |
| 2018-09-30 | (m) | $796.10M | (m) | (m) |
| 2018-06-30 | (m) | $772.60M | (m) | (m) |
| 2018-03-31 | (m) | $778.20M | (m) | (m) |
| 2017-12-31 | (m) | $781.70M | (m) | (m) |
| 2017-09-30 | (m) | $784.10M | (m) | (m) |
| 2017-06-30 | (m) | $771.40M | (m) | (m) |
| 2017-03-31 | (m) | $757.30M | (m) | (m) |
| 2016-12-31 | (m) | $750.90M | (m) | (m) |
| 2016-09-30 | (m) | $747.80M | (m) | (m) |
| 2016-06-30 | (m) | $753.80M | (m) | (m) |
| 2016-03-31 | (m) | $757.30M | (m) | (m) |
| 2015-12-31 | (m) | $746.70M | (m) | (m) |
| 2015-09-30 | (m) | $737.80M | (m) | (m) |
| 2015-06-30 | (m) | $723.10M | (m) | (m) |
| 2015-03-31 | (m) | $721.98M | (m) | (m) |
| 2014-12-31 | (m) | $724.92M | (m) | (m) |
| 2014-09-30 | (m) | $744.59M | (m) | (m) |
| 2014-06-30 | (m) | $778.22M | (m) | (m) |
| 2014-03-31 | (m) | $763.57M | (m) | (m) |
| 2013-12-31 | (m) | $737.12M | (m) | (m) |
| 2013-09-30 | (m) | $682.20M | (m) | (m) |
| 2013-06-30 | (m) | $613.16M | (m) | (m) |
| 2013-03-31 | (m) | $572.01M | (m) | (m) |
| 2012-12-31 | (m) | $545.32M | (m) | (m) |
| 2012-09-30 | (m) | $518.99M | (m) | (m) |
| 2012-06-30 | (m) | $496.00M | (m) | (m) |
| 2012-03-31 | (m) | $470.45M | (m) | (m) |
| 2011-12-31 | (m) | $443.05M | (m) | (m) |
| 2011-09-30 | (m) | $420.68M | (m) | (m) |
| 2011-06-30 | (m) | $402.08M | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | $362.65M | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | $326.53M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |